These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20017577)

  • 61. Developmental toxicity testing in the 21st century: the sword of Damocles shattered by embryonic stem cell assays?
    Seiler A; Oelgeschläger M; Liebsch M; Pirow R; Riebeling C; Tralau T; Luch A
    Arch Toxicol; 2011 Nov; 85(11):1361-72. PubMed ID: 22008952
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterising hepatic mitochondrial function as a model for systemic toxicity: a commentary.
    Leach AR; Wallace K; Alepee N; Daston G; Humphris C; Manou I; Modi S; Ringeissen S; Whelan M; Kimber I
    Toxicology; 2012 Dec; 302(1):96-9. PubMed ID: 23126011
    [No Abstract]   [Full Text] [Related]  

  • 63. A three-tier QSAR modeling strategy for estimating eye irritation potential of diverse chemicals in rabbit for regulatory purposes.
    Basant N; Gupta S; Singh KP
    Regul Toxicol Pharmacol; 2016 Jun; 77():282-91. PubMed ID: 27018829
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [INVITOX 2002: 12th International workshop on in vitro toxicology].
    Boess F; Scholz G; Spielman H
    ALTEX; 2003; 20(1):36-9. PubMed ID: 12674101
    [No Abstract]   [Full Text] [Related]  

  • 65. Green Toxicology-Know Early About and Avoid Toxic Product Liabilities.
    Maertens A; Hartung T
    Toxicol Sci; 2018 Feb; 161(2):285-289. PubMed ID: 29267930
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gaining acceptance for the use of in vitro toxicity assays and QIVIVE in regulatory risk assessment.
    Meek ME; Lipscomb JC
    Toxicology; 2015 Jun; 332():112-23. PubMed ID: 25598226
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The fish embryo toxicity test as an animal alternative method in hazard and risk assessment and scientific research.
    Embry MR; Belanger SE; Braunbeck TA; Galay-Burgos M; Halder M; Hinton DE; Léonard MA; Lillicrap A; Norberg-King T; Whale G
    Aquat Toxicol; 2010 Apr; 97(2):79-87. PubMed ID: 20061034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ECVAM and pharmaceuticals.
    Vanparys P
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():221-3. PubMed ID: 12513680
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Protein biomarkers for in vitro testing of toxicology.
    Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K
    Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.
    Bueters T; Ploeger BA; Visser SA
    Drug Discov Today; 2013 Sep; 18(17-18):853-62. PubMed ID: 23665277
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity.
    Van Summeren A; Renes J; van Delft JH; Kleinjans JC; Mariman EC
    Toxicol In Vitro; 2012 Apr; 26(3):373-85. PubMed ID: 22274661
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In silico methods for early toxicity assessment.
    Merlot C
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Validation of innovative technologies and strategies for regulatory safety assessment methods: challenges and opportunities.
    Stokes WS; Wind M
    ALTEX; 2010; 27(3):87-95. PubMed ID: 21113563
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Systematically evaluating read-across prediction and performance using a local validity approach characterized by chemical structure and bioactivity information.
    Shah I; Liu J; Judson RS; Thomas RS; Patlewicz G
    Regul Toxicol Pharmacol; 2016 Aug; 79():12-24. PubMed ID: 27174420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The new revolution in toxicology: the good, the bad, and the ugly.
    Davis M; Boekelheide K; Boverhof DR; Eichenbaum G; Hartung T; Holsapple MP; Jones TW; Richard AM; Watkins PB
    Ann N Y Acad Sci; 2013 Mar; 1278():11-24. PubMed ID: 23488558
    [TBL] [Abstract][Full Text] [Related]  

  • 78. An integrated decision-tree testing strategy for repeat dose toxicity with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Feb; 36(1):93-101. PubMed ID: 18333717
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ECVAM's activities on computer modelling and integrated testing.
    Worth AP
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():133-7. PubMed ID: 12513665
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chemical safety without animals.
    Westmoreland C; Carmichael PL
    Nat Biotechnol; 2014 Jun; 32(6):541-3. PubMed ID: 24911497
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.